Agree. My thoughts: - If they got FDA compass
Post# of 148288
- If they got FDA compassionate care they would have announced it immediately because they care desperately about actually saving lives.
- We know trial enrollment is VERY slow after the Remdesivir announcement, a baffling mis-step that has cost many lives. And a primary focus is getting those trials enrolled so results can be announced.
- It's unlikely to be financial deal given the CFO isn't on the call.
Lalezari is speaking which means it may be an appeal to the media to get exposure on these trials and the results thus far. The science is good. We need press; we need physicians to request it for emergency use; and we need more trial enrollments. That's likely the objective here.
So please let's keep expectations low so we don't see more turbulence at a time when we need to be supporting the executive team to get the job done.